Understanding the molecular underpinnings of cancer is of critical importance to the development of targeted intervention strategies. Identification of such targets, however, is notoriously difficult and unpredictable. Malignant cell transformation requires the cooperation of a few oncogenic mutations that cause substantial reorganization of many cell features 1 and induce complex changes in gene expression patterns [2] [3] [4] [5] [6] . Genes critical to this multifaceted cellular phenotype have therefore only been identified after signalling pathway analysis [7] [8] [9] [10] or on an ad hoc basis 4, [11] [12] [13] [14] . Our observations that cell transformation by cooperating oncogenic lesions depends on synergistic modulation of downstream signalling circuitry [15] [16] [17] suggest that malignant transformation is a highly cooperative process, involving synergy at multiple levels of regulation, including gene expression. Here we show that a large proportion of genes controlled synergistically by loss-of-function p53 and Ras activation are critical to the malignant state of murine and human colon cells. Notably, 14 out of 24 'cooperation response genes' were found to contribute to tumour formation in gene perturbation experiments. In contrast, only 1 in 14 perturbations of the genes responding in a non-synergistic manner had a similar effect. Synergistic control of gene expression by oncogenic mutations thus emerges as an underlying key to malignancy, and provides an attractive rationale for identifying intervention targets in gene networks downstream of oncogenic gain-and loss-of-function mutations.
To identify genes regulated synergistically by cooperating oncogenic mutations at genomic scale, we compared messenger RNA expression profiles of young adult murine colon (YAMC) cells with those of YAMC cells expressing mutant p53 175H (mp53), activated H-RasV12 (Ras) or both mutant proteins together (mp53/Ras) 17 using Affymetrix microarrays. Using a stepwise procedure, we first identified 538 differentially expressed genes between mp53/Ras and YAMC control cells with a statistical cutoff at P , 0.01 (N-test, Westfall-Young adjusted). A further subset of 95 annotated genes that responded synergistically (28 upregulated, 67 downregulated) to the combination of mutant p53 and Ras proteins (termed 'cooperation response genes', CRGs) was then determined using a synergy score as described in Methods (Fig. 1 , Supplementary Table 1 and  Supplementary File 1) . Expression values and synergy scores for the CRGs derived from TaqMan low-density quantitative polymerase chain reaction (qPCR) array data showed strong positive correlation with the values for the same genes obtained from microarray analysis (Supplementary Figs 1 and 2, Supplementary Table 2 and Supplementary File 2) . CRG identification was therefore confirmed by independent methods, with final CRG selection based on microarray data due to the higher sample replication in this dataset.
CRGs encode proteins which are involved in the regulation of cell signalling, transcription, apoptosis, metabolism, transport or adhesion (Fig. 2a, b co-regulation is found in primary human colon cancer and our murine colon cancer cell model ( Fig. 2c and Supplementary Fig. 3 175H and/or activated H-RasV12 in a non-cooperative manner (non-CRGs). Perturbed genes were chosen across a broad range of biological functions, levels of differential expression and synergy scores (Fig. 2, Supplementary  Fig. 4 and Supplementary File 3) . Gene perturbations were carried out in mp53/Ras cells with the goal of re-establishing mRNA expression of the manipulated genes to levels relatively close to those found in YAMC control cells, and to monitor subsequent tumour formation following subcutaneous injection of these cells into immunocompromised mice. Of the perturbed genes, 18 were upregulated and 20 were downregulated in mp53/Ras cells, relative to YAMC.
Reversal of the changes in CRG expression significantly reduced tumour formation by mp53/Ras cells in 14 out of 24 cases (Fig. 3a, left  panel, Fig. 4a, c, Supplementary Fig. 5a and Supplementary Table 3) , indicating a critical role in malignant transformation for a surprisingly large fraction of these genes. Perturbation of Plac8, Jag2 and HOXC13 gene expression had the strongest effects. We also combined perturbations of two CRGs, Fas and Rprm, that alone produced significant yet milder changes in tumour formation. Combination of these two CRGs yielded significantly increased efficacy in tumour inhibition as compared with the respective single perturbations (Fig. 4e, Supplementary Fig. 5b and Supplementary Table 4) . Therefore, even genetic perturbations of CRGs with relatively smaller effects when examined on their own show evidence of being essential when analysed in combination. In contrast to the multitude of CRG-related effects on tumour inhibition, out of the 14 non-CRG perturbations, only one showed a significant reduction in tumour formation of mp53/Ras cells (Fig. 3a, right panel, Supplementary Fig. 6 and Supplementary Table 5 ). Taken together, our data suggest that among the genes differentially expressed in cancer cells, malignant transformation strongly relies on the class of genes synergistically regulated by cooperating oncogenic mutations (Fig. 3b and Supplementary Fig. 7) .
Genetic perturbation experiments were carried out using retrovirus-mediated re-expression of corresponding complementary DNAs (cDNAs) for downregulated genes (Supplementary Table 6 ) and short hairpin RNA (shRNA)-dependent stable knockdown using multiple independent targets for overexpressed genes (Supplementary Table 7 ). In addition, Plac8 knockdown was functionally rescued by expression of shRNA-resistant Plac8 (Fig. 4a) , confirming the specificity of the Plac8 loss-of-function experiments. The extent of all gene perturbations was assessed by qPCR ( Supplementary Fig. 8 ). As expected, the genetic perturbations disrupt tumour formation downstream of the initiating oncogenic mutations. Expression of both mutant p53 and activated Ras proteins remained unaffected by all genetic manipulations that alter the formation of tumours ( Supplementary Fig. 9 ). Moreover, gene perturbations distinguished tumour growth from in vitro cell proliferation, as they generally did not affect cell accumulation in tissue culture (Supplementary Fig. 10 ).
Perturbations of CRGs in human cancer cells (Fig. 4b, d , f, Supplementary Fig. 11 and Supplementary Tables 8, 9) had similarly strong tumour inhibitory effects to those in the genetically tractable murine mp53/Ras cells, as assessed by xenografts in nude mice. Perturbations of both upregulated and downregulated CRGs (that is, Dffb, Fas, HOXC13, Jag2, Perp, PLAC8, Rprm, Zfp385 and Fas/ Rprm ) were performed in human DLD-1 and/or HT-29 colon cancer cell lines using retroviruses ( Supplementary Fig. 12 , Supplementary Tables 6 and 10) as described above. Similar to mp53/Ras cells, both human cancer cell lines have p53 mutations, whereas with K-Ras (DLD-1) and B-Raf (HT-29) mutations they express activated members of the Ras-Raf signalling pathway distinct from activated H-Ras in mp53/Ras cells. In addition, DLD-1 and HT-29 cells carry further oncogenic lesions such as APC and PIK3CA mutations, with HT-29 cells also having a mutation in SMAD4 (see Supplementary Methods for references). The genetic perturbations had no effect on mutant Ras-Raf or p53 protein expression levels in both DLD-1 and HT-29 cells (Supplementary Fig. 13 ), indicating disruption of the cancer phenotype downstream of oncogenic mutations. Taken together, these experiments indicate the relevance of CRGs to cancer in a variety of backgrounds and genetic contexts.
The data described here indicate that the cooperative nature of malignant cell transformation depends, to a considerable degree, on a class of downstream effector genes regulated synergistically by multiple oncogenic mutations. We show that these CRGs contain a large fraction of genes (14 out of 24 tested) that are critical to the malignant phenotype, and that their perturbation-singly or in combination-can inhibit formation of tumours containing multiple oncogenic lesions, including p53 deficiency. In contrast, few of the genes differentially expressed in a non-synergistic manner (1 out of 14) significantly reduced tumour growth on perturbation. Synergistic behaviour found in gene expression data thus seems highly informative for identification of genes that are critically involved in malignant cell transformation (Fig. 3b) , and provides a rational path to discovery of both cancer-cell-specific vulnerabilities and targets for intervention in cancer cells harbouring multiple mutations, including p53 loss-of-function.
CRGs represent a set of 95 annotated cellular genes, many of which have been associated with human cancer by virtue of altered gene expression ( Fig. 2c and Supplementary Table 1) . They are involved in the regulation of cell signalling, transcription, apoptosis and metabolism, and on the basis of our data represent key control points in many facets of cancer cell behaviour. We thus consider CRGs as critical nodes in gene networks underlying the malignant phenotype, providing an attractive rationale to explain why several features of cancer cells emerge simultaneously out of the interaction of a few genetic lesions 17 . Among CRGs and other differentially expressed effector genes we have also identified examples of genes that when perturbed produce significantly larger tumours (Fig. 3 and Supplementary Tables 3 and  5 ). This is consistent with the notion that oncogenic mutations can strongly induce antiproliferative cellular stress responses [18] [19] [20] [21] . The existence of genes that restrict tumour formation while responding to oncogenic mutations supports the idea that the state of malignant transformation occurs as the result of a finely tuned balance between opposing signals generated by oncogenic mutations [15] [16] [17] 20, 22, 23 . It is thus reasonable to speculate that tumour suppression via perturbation of CRGs as we have demonstrated may involve the disruption of this delicate balance. In fact, such targeted disruption downstream of oncogenic mutations may allow selective cancer cell deconstruction, yielding intervention strategies with high specificity for cancer cells.
For the 14 CRGs with tumour-inhibitory perturbations, a clear causal role in tumour formation downstream of oncogenic mutations has been shown here, to our knowledge, for the first time. Moreover, our data indicate that both gene extinctions (eight genes) and gene inductions (six genes) have important roles in this process. For example, we show that re-expression of the downregulated CRGs Jag2 (a Notch ligand) or HOXC13 (a homeobox transcription factor), as well as shRNA-dependent knockdown of Plac8 gene expression, are each strongly tumour inhibitory in p53-defective murine and human cancer cells. Both Notch signalling 24 and HOXC13 (ref. 25) can have oncogenic functions in haematopoietic malignancies but are involved in promoting differentiation of epithelial cells 26, 27 , consistent with the tumour-inhibitory function of Jag2 and HOXC13 in the context of the solid-tumour models investigated here. Plac8 is a little-investigated gene encoding a cysteine-rich highly conserved peptide, expressed in placenta, haematopoietic and epithelial cells, which is non-essential for mouse development 28 . Plac8 can suppress p53 when overexpressed 29 ; however, its essential role for tumour formation of p53-deficient cancer cells is unexpected. Among the eight downregulated CRGs is Zfp385, another gene of unknown function. Moreover, there are several pro-apoptotic and/ or anti-proliferative genes such as Perp, Rprm, Fas, Dffb and Wnt9a, indicating that Ras activation and p53 deficiency cooperate to extinguish the expression of multiple growth-inhibitory genes, each of which contributes significantly to restricting tumour growth in the YAMC model when re-expressed. Out of these genes, Perp, Rprm and Fas have been previously identified as direct p53 targets, suggesting that their regulation by p53 is highly conditional on Ras activity (Supplementary Table 1 and references therein). Most of the upregulated CRGs contributing to tumour growth affect signal transduction. This includes Fgf7, Rgs2, Gpr149, an uncharacterized orphan seven-transmembrane receptor, and Sod3, which acts on signalling via modulation of metabolites 30 . Here we show a role in promoting tumour growth for all of these genes (including Pla2g7).
The efficacy of CRG perturbations performed in human colon cancer cells was comparable to that in the murine colon cell transformation model, suggesting dependence of the malignant state on a similar set of genes in both backgrounds. This is notable in light of the fact that these human cancer cells carry oncogenic mutations in genes in addition to Ras or Raf and p53, and suggests that CRGs may have a large involvement in the generation and maintenance of the cancer cell phenotype in a variety of contexts. CRGs may therefore provide a valuable source for identification by rational means of the much sought 'Achilles' heel' in human cancer.
METHODS SUMMARY
Cells. YAMC cells and derivation of cells with multiple oncogenic lesions 17 are described in Supplementary Information. Microarray experiments, statistical analysis and CRG identification. Polysomal RNA was collected to obtain gene expression profiles reflective of protein synthesis rates. Expression values were obtained using the RMA procedure with background correction in Bioconductor (http://www.bioconductor. org). Differentially expressed genes were identified by the step-down WestfallYoung procedure in conjunction with the permutation N-test; the family-wise error rate was less than 0.01. Genes that respond synergistically to the combination of mutant p53 and activated Ras (CRGs) were selected by the following procedure. Let a represent mean expression value for a given gene in mp53 cells, b correspond to the mean expression value for the same gene in Ras cells, and d signify mean expression value for this gene in mp53/Ras cells. Then, the criterion defines CRGs as azb d ƒ0:9 for genes overexpressed in mp53/Ras cells and as d a z d b ƒ0:9 for genes underexpressed in mp53/Ras cells, as compared to controls. To assess robustness of synergy scores, jackknife sub-sampling was used to generate estimated P values for these scores. TaqMan low-density arrays (Applied Biosystems) were used to test gene expression differences observed by Affymetrix arrays independently. Genetic perturbation of gene expression. cDNAs expressed via pBabe retroviral vectors or shRNA in pSuper-retro vectors were used to generate gene perturbations. These were tested by comparison of RNA expression levels in empty vector-infected cells and cells subjected to gene perturbation via SYBR Green qPCR with gene-specific primers. Xenograft assays. 
LETTERS
Significance of difference in tumour size was calculated by means of the Wilcoxon signed-ranks test and the t-test, using directly matching vector control cells for each perturbation.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
